Alzheimer s disease (AD) is a neurodegenerative disease that
robs the minds of our elderly population. Approximately one in
every eight adults over the age of 65 and nearly half of those over
85 are afflicted with this disease. The aging population in
developed societies will impose an ever increasing socioeconomic
threat in the future. Current medicines for AD patients are mainly
symptomatic treatments and a huge unmet medical need exists to slow
the progression of this disease. A great deal of research has been
dedicated to understanding the pathogenesis of AD from which comes
many ideas for intervening with its progression. Some of these
ideas have been fast-tracked to clinical trials due to the
availability of medicines with proven clinical efficacies for other
diseases (e.g. atorvastatin, simvastatin, rosiglitazone and
clioquinol) while others represent novel chemical entities (e.g.
glycogen synthase kinase-3 inhibitors).
This volume will first review existing cholinesterase inhibitors
prescribed for AD patients followed by some target mechanisms with
ongoing clinical trials. It offers a glimpse of what our future
medicine cabinets may look like for AD patients. It also provides
an interesting read on why and how current medicines for other
indications could potentially be used to treat AD."
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!